Life Sciences and Healthcare

LSPN Live | Strategies in Second Medical Use Cases

Published on 22nd Dec 2021

Tim Harris and Chris Pratt, both experienced life sciences lawyers in Osborne Clarke's disputes team, explain the legal risks when a medical product has been authorised for a new treatment, and provide an overview of recent legal developments. In this discussion, they discuss strategies and tactics for the innovator companies needing to protect their research and investment when existing therapeutics are repurposed for a novel indication. They also look at the steps both generics and biosimilars should take to minimise their risks when launching a product protected by "second medical use" patents and how to navigate the legal and practical hurdles across jurisdictions.  

Share
Interested in hearing more from Osborne Clarke?

* This article is current as of the date of its publication and does not necessarily reflect the present state of the law or relevant regulation.

Connect with one of our experts

Interested in hearing more from Osborne Clarke?

Related articles